Drug test for IgA? No—anti-PLA2R positive immune kidney disease
Part of Kidney & urinary clinical trials.
This Phase 2 trial studies AP1189 in people with a specific immune-related kidney disease called iMN and very high urine protein. It aims to see whether the drug is safe and tolerable and if it can reduce protein in the urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 85 years old.
- You were diagnosed with iMN within the last 6 months.
- Your blood test must show anti-PLA2 receptor positive results within the last 6 months.
- You must have severe protein in your urine plus specific kidney lab results, and kidney filtering (eGFR) must be above 30.
- You must live in Denmark or Norway or Sweden (this trial has country-specific rules for women).
- Your blood pressure must be controlled, and you must have been on an ACE-inhibitor or ARB for at least 1 month (or you could not take it due to side effects).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 2a trial tests an experimental drug called RG002C0106 in people with primary IgA nephropathy. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This study tests an experimental drug called MY008211A for people with IgA nephropathy (a kidney disease). It aims to see if it can safely reduce protein in the urine and protect kidney function.
This trial tests a medicine called CM313 in people with IgA nephropathy, a kidney disease. It may help reduce protein in the urine, which is a sign of kidney damage.
This study tests an experimental drug called NTQ5082 for people with IgA nephropathy. It aims to see if the drug can reduce protein in the urine and protect kidney function.
This phase 3 trial tests an experimental drug (HRS-5965) for people with IgA nephropathy (a kidney disease). It aims to find out if the drug can help reduce protein in the urine and protect kidney function. To join, you must have had a kidney biopsy showing IgA nephropathy within the past 8 years and have significant protein in your urine despite taking standard treatments.
This trial tests an experimental medicine called NM8074 for people with IgA nephropathy, a type of kidney disease. It aims to see if NM8074 can help protect your kidneys and reduce damage.
Hear when a new Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.